## Ronald Vender

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11596344/publications.pdf

Version: 2024-02-01

	1163117	1588992	
860	8	8	
citations	h-index	g-index	
8	8	1139	
docs citations	times ranked	citing authors	
	citations 8	860 8 citations h-index	

#	Article	IF	CITATIONS
1	Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial. Lancet, The, 2021, 397, 475-486.	13.7	136
2	A headâ€toâ€head comparison of ixekizumab vs. guselkumab in patients with moderateâ€toâ€severe plaque psoriasis: 12â€week efficacy, safety and speed of response from a randomized, doubleâ€blinded trial. British Journal of Dermatology, 2020, 182, 1348-1358.	1.5	117
3	Efficacy of Secukinumab in the Treatment of Moderate to Severe Plaque Psoriasis in the North American Subgroup of Patients: Pooled Analysis of Four Phase 3 Studies. Dermatology and Therapy, 2018, 8, 17-32.	3.0	14
4	A Treatment Algorithm for Moderate to Severe Atopic Dermatitis in Adults. Journal of Cutaneous Medicine and Surgery, 2018, 22, 78-83.	1.2	17
5	Management of Moderate to Severe Plaque Psoriasis: The Emerging Role of IL-17 Inhibition. Journal of Cutaneous Medicine and Surgery, 2017, 21, 2S-40S.	1.2	9
6	Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1Âyear: Results from the CLEAR study. Journal of the American Academy of Dermatology, 2017, 76, 60-69.e9.	1.2	258
7	Review of Systemic Treatment Options for Adult Atopic Dermatitis. Journal of Cutaneous Medicine and Surgery, 2017, 21, 31-39.	1.2	42
8	Interleukin 17A: Toward a new understanding of psoriasis pathogenesis. Journal of the American Academy of Dermatology, 2014, 71, 141-150.	1.2	267